PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-37.55%
Both yoy net incomes decline, with TRVN at -2.47%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
14.84%
D&A growth well above TRVN's 1.22%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
No Data
No Data available this quarter, please select a different quarter.
0.81%
SBC growth while TRVN is negative at -12.90%. John Neff would see competitor possibly controlling share issuance more tightly.
106.29%
Well above TRVN's 1.93% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
81.80%
Some yoy usage while TRVN is negative at -319.41%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
No Data
No Data available this quarter, please select a different quarter.
9.51%
Operating cash flow growth below 50% of TRVN's 33.33%. Michael Burry would see a serious shortfall in day-to-day cash profitability.
38.16%
CapEx growth of 38.16% while TRVN is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
38.16%
We expand invests by 38.16% while TRVN is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
No Data
No Data available this quarter, please select a different quarter.
1171.17%
Lower share issuance yoy vs. TRVN's 650400.00%, implying less dilution. David Dodd would confirm the firm still has enough capital for expansions.
No Data
No Data available this quarter, please select a different quarter.